Saval Khanal is a Research Fellow in Health Economics within the Health Economics for Life Sciences and Medicine (HELM) group at King’s College London. His work focuses on conducting economic evaluations to inform health policy decisions. At King’s, Saval is involved in several high-impact projects, including:

• PREVENT-PE: Economic evaluation of pre-eclampsia prevention through timed birth at term.
• KFRE Study: Economic evaluation of improving the predictive performance of the Kidney Failure Risk Equation (KFRE) using linked UK Renal Registry data to enhance risk communication for ethnically diverse populations.
• IMPROVE Trial: Economic evaluation of PR-Buddies to improve completion rates of pulmonary rehabilitation.

Saval holds a PhD in Pharmacoepidemiology and Pharmacoeconomics from the University of Queensland, Australia. With extensive experience across academic, research, and consultancy sectors, he specialises in cost-effectiveness modelling, budget impact analysis, and patient-reported outcomes analysis. These skills enable him to assess the value of healthcare interventions and provide evidence to guide policy and clinical decisions.

Before joining King’s College London, Saval was a Senior Research Associate at Health Economics Consulting, University of East Anglia, where he led projects on AI-enhanced diagnostics, mental health support systems, and early economic assessments for movement monitoring technologies. He also contributed to NICE appraisals and developed advanced cost-effectiveness models at Warwick Evidence based in the University of Warwick.

Saval’s academic career includes research fellowships at Centre for Applied Health Economics based in Griffith University and Behaviour Science Group at Warwick Business School, as well as a lectureship in Pharmacoeconomics and Management at Tribhuvan University, Nepal. He began his career as a hospital and clinical pharmacist at Manipal Teaching Hospital, Nepal. The full list of Saval’s publications can be found here: Full List of Publications

An active member of professional organisations, including the International Pharmaceutical Federation (FIP), International Health Economics Association (iHEA), Health Economics Study Group (HESG) and the Royal Pharmaceutical Society, Saval is dedicated to advancing health economics research and mentoring the next generation of health economists.

PhD supervision

I welcome potential PhD students to discuss the opportunities around economic evaluation of health, health technology assessment health service utilisation and multi-criteria decision analysis.